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Letters to the Editor 
Invited letter concerning: Clinical and left 
ventricular function outcomes up to five years 
after dynamic cardiomyoplasty 
To the Editor: 
The evolution of the clinical use of skeletal muscle 
assistance to support he failing heart has not conformed 
to an idealized scientific progression from observation to 
experimentation to patient application. Interestingly, the 
vast majority of experimental work has been performed to 
devise auxiliary ventricles that function as diastolic coun- 
terpulsators. Yet, this mode of skeletal muscle assistance 
has not been brought o the clinical arena. The plethora of 
experimental studies on the efficacy of synchronizing 
skeletal muscle wrapped directly around the heart to 
contract during systole has mostly followed the initial 
clinical experience and seemed predicated more on 
technical feasibility rather than solid animal data demon- 
strating improved hemodynamics. Despite no definitive 
experimental study showing consistent and long-term im- 
provement in cardiac function and few clinical reports of 
objective improvements in hemodynamics and patient 
longevity, dynamic ardiomyoplasty is applauded by many 
surgeons as an alternative therapy to cardiac transplanta- 
tion for patients who either do not meet the stringent 
screening criteria or may not receive timely organ dona- 
tion because of donor shortages. 
In this context, the article by Dr. Moreira and associ- 
ates I as reported in this issue is particularly enticing. 
Unfortunately, an objective evaluation of the presented 
data provides a much less sanguine assessment of the 
efficacy of this operation. First, the 5-year follow-up is 
anecdotal because only four of the patients were observed 
this long and statistical significance for improvement in
left ventricular stroke work is lost after 36 months. In fact, 
improvement in global ejection phase indices of right and 
left ventricular function are lost at 24 and 12 months, 
respectively, after the operation. One may also question 
the physiologic significance of an increase in left ventric- 
ular ejection fraction from 19% to 23% or 24% as 
measured by radioisotope scintigraphy. Alternatively, dy- 
namic cardiomyoplasty may be beneficial by preventing 
progression of ventricular dilatation as opposed to im- 
proving ejection fraction. However, the authors do not 
provide the end-diastolic volumes at which maintenance 
of stroke volume occurs to adjudicate this issue. This 
would have important implications in regard to ventricular 
wall stress and arrhythmogenesis. 
The survival data are even less impressive. For the 
entire group, actuarial survival at 3 to 5 years is 42.5% _+ 
11.8%. No patient with New York Heart Association class 
IV symptoms urvived for 3 years and half of these 
patients had died by one year. Patients in class III had only 
a 60% 3-year survival. Moreover, these patients had 
idiopathic dilated cardiomyopathy, and perhaps their 
prognosis is, in fact, better than that of patients who have 
ischemic ardiomyopathy. Is this truly an alternative for 
cardiac transplantation? Is this a viable alternative for 
medical therapy? 
Although the authors mention that they had a non- 
matched medically treated control group, I think it is 
imperative that an objective description of these patients 
with "medically refractory" heart failure be used to truly 
identify similar patient cohorts. The prognosis of patients 
eligible for cardiac transplantation is clearly affected by 
their degree of pulmonary hypertension, response to exer- 
cise, maximal oxygen consumption, and response to aggres- 
sive "tailored" medical therapy. 2 The decision to list a 
patient for transplantation (or perhaps to perform a car- 
diomyoplasty) is made during a period of relative clinical 
instability. Yet, the majority of patients improve and are 
discharged home to await organ donation. Interestingly, 
Stevenson and associates 3 have found that if a transplant 
candidate survives 6 months without an allograft, the subse- 
quent 24 month survival is 80%. Granted, the attrition rate 
during the first 6 months is significant. Yet, most of these 
patients have class IV disease and would have a similarly 
poor outcome when subjected to cardiomyoplasty. The co- 
hort with the best results in this series, that is, patients with 
class III symptoms, should also be stringently evaluated. 
Mancini and associates 4 measured peak exercise oxygen 
consumption i a large series of patients referred for cardiac 
transplantation. I  a group who had class III symptoms but 
had a peak oxygen consumption of 19 ml/kg per minute, 
survival at 1 and 2 years with continued medical therapy was 
94% and 84%, respectively. For the efficacy of cardiomyo- 
plasty versus medical therapy to be adjudicated, the patients 
must be evaluated by more than functional class and ejection 
fraction. 
I laud the intrepid surgical efforts of Dr. Moreira and 
colleagues. However, the fact that an operation isnew and 
can be performed oes not automatically confer benefit. I 
wish that one of the groups performing this procedure 
would find the courage or honesty to insert in the discus- 
sion that cardiomyoplasty may really have only limited or 
no value. If the patient is too sick, it does not work. If the 
patient is not too sick, perhaps "tailored" medical therapy 
is the best option. Surgeons hould no longer hide behind 
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the "better patient selection" excuse for defining the 
future role of skeletal muscle assistance. 
Norman A. Silverman, MD 
Division Head 
Cardiac and Thoracic Surgery 
Henry Ford Hospital 
2799 West Grand Blvd. 
Detroit, MI 48202 
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12/8/60675 
Aortopulmonary paraganglioma, a rare tumor 
To the Editor: 
I read with interest the letter on aortopulmonary para- 
ganglioma by Castafion and associates, 1 who referred also 
to our case of intrathoracic chemodectoma (or paragan- 
glioma) with multiple localizations, z I would like to recall 
the Carney triad of extraadrenal paraganglioma, pulmo- 
nary chondroma, and gastrointestinal leiomyo(sarco)ma. 
After reviewing the clinical data and the available histo- 
logic data on our case, Carney included our case in a series 
of patients with the triad from the Mayo Clinic and from 
the literature) 
Our case concerned a female patient who underwent 
at the age of 31 years a resection of an anterosuperior 
mediastinal chemodectoma. An esophageal nomaly had 
been discovered at the age of 16 years, during an episode 
of vomiting, but because the patient was afterward asymp- 
tomatic, she refused any further investigation of the 
esophagus. Seventeen years later the patient had a second 
operation. An aortopulmonary chemodectoma was re- 
sected and a pulmonary osteochondroma of the lingula 
was enucleated. The esophagus was not explored accord- 
ing to the wish of the patient. Two years later, a small 
tumor in the left upper lung lobe was visible and was 
considered to be a new or recurrent benign pulmonary 
hamartochondroma, butagain 2 years later an inoperable 
squamous cell carcinoma of the left main bronchus was 
discovered and the patient died 3 months later at the age 
of 52 years. Postmortem examination was refused by the 
relatives, so that the histologic type of the esophageal 
tumor is still unknown. We believed that the long-lasting 
esophageal nomaly was a benign leiomyoma nd consid- 
ered that our patient had the Carney triad. 
With regard to the case of aortopulmonary paragangli- 
oma reported by Castafion's group, aI have some recom- 
mendations and some comments. 
I recommend regular follow-up of the patient, exclusion 
Of other localizations of the paraganglioma, and exclusion 
of the triad of Carney. There is no chronologic sequence 
in the appearance of these three tumors, and their occur- 
rence is more than coincidence) Moreover, malignancy of 
each part of the triad is possible, z'3 
The risk of lung cancer is increased in patients with 
chondromatous hamartoma, whether the hamartoma it- 
self or the fibrous scar or whether both tumors have 
common risk factors. 4 The spatial association was present 
in our case, and the question arises whether the enucle- 
ation of a hamartoma should not be altered in a segmental 
resection. In our case a new small tumor appeared 2 years 
after the enucleation and was, without proof, considered 
to be benign, but another 2 years later lung cancer was 
discovered in the same area. 
Finally, patients with pulmonary hamartoma have a 
high incidence of associated anomalies and benign tumors 
but also an increased susceptibility to development of 
malignant tumors. Therefore, the clinical significance of 
pulmonary hamartoma is in the workup and lifelong 
follow-up of those patients. 5 
Leon 1<2 Lacquet, MD 
Professor and Chairman 
Thoracic and Cardiac Surgery 
University Hospital St. Radboud PB 9101 
6500 HB Nijmegen, The Netherlands 
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12/8/55995 
Anomalous origin of the left coronary artery from 
the pulmonary artery: New technique or 
modification of "old" technique 
To the Editor." 
We read with interest he article by Tashiro and asso- 
ciates, 1 "Anomalous Origin of the Left Coronary Artery 
